Goldman Sachs
MTCR

Goldman Sachs’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Goldman Sachs’s Portfolio MTCR Stock Details MTCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-15,744
Closed -$10K – 6868
2022
Q1 		$10K Sell
15,744
-194,691
-93% -$102K ﹤0.01% 6481
2021
Q4 		$142K Buy
210,435
+194,694
+1,237% +$347K ﹤0.01% 6019
2021
Q3 		$54K Sell
15,741
-9,562
-38% -$29.8K ﹤0.01% 6033
2021
Q2 		$96K Buy
25,303
+14,694
+139% +$60.8K ﹤0.01% 5956
2021
Q1 		$66K Sell
10,609
-8,431
-44% -$74.7K ﹤0.01% 5908
2020
Q4 		$150K Sell
19,040
-79,060
-81% -$725K ﹤0.01% 5184
2020
Q3 		$1M Buy
+98,100
New +$1M ﹤0.01% 4074

Other funds holding MTCR

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Goldman Sachs's MTCR Position: Q2 2022 in Review

Goldman Sachs sold out of Metacrine, Inc. Common Stock (MTCR) in Q2 2022, closing a stake of 15,744 shares — an estimated $10K sold.

Goldman Sachs first reported a position in MTCR in Q3 2020 and held it in 7 quarters. The position peaked at $1M in Q3 2020. 25 funds tracked by Wall St. Rank hold MTCR as of Q2 2022.

  • Goldman Sachs reported no remaining Metacrine, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Goldman Sachs sold 15,744 Metacrine, Inc. Common Stock shares in Q2 2022, an estimated $10K.
  • Goldman Sachs first reported a position in Metacrine, Inc. Common Stock in Q3 2020 and held it in 7 quarters.
  • Goldman Sachs's Metacrine, Inc. Common Stock position peaked at $1M in Q3 2020.
  • 25 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q2 2022.

Based on Goldman Sachs's 13F filing for Q2 2022, filed 15 Aug 2022.